Andrea Fuentes, MD
Neurology · San Diego, CANPI 1003342585
Payments from drug & device makers
What this record shows
This record is dominated by grants: $26,500 of the $28,888 with a category attached, or 91.7%. 5 manufacturers reported payments, led by Boston Scientific at 57.7% of the total. Reporting peaked in 2021 at $16,300 and has fallen 97.8% since, to $357 in 2025.
Across 56 payments — averaging $515.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$17K
- Medtronic$12K
- AbbVie$234
- Abbott$28
- Biohaven Pharmaceuticals, Inc.$20
What the payments were for
- Grants$26,50092%
- Travel & lodging$9573%
- Food & beverage$1,2824%
- Education$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $16,671 |
| Medtronic | 33 | $11,935 |
| AbbVie | 11 | $234 |
| Abbott | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$16,250
- ACTIVA$6,250
- ACTIVA PC$4,000
- PERCEPT PC BRAINSENSE$1,078
- GENERAL DBS$111
How this compares
$28,888 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $64,690 |
| RytaryCarbidopa/Levodopa | 24 | $48,747 |
| Carbidopa | 14 | $13,450 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 139 | $6,961 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 76 | $3,515 |
| AmantadineAmantadine Hcl | 44 | $2,914 |
| Mirtazapine | 31 | $928 |
| Clonazepam | 26 | $773 |
| Gabapentin | 11 | $640 |
| Primidone | 12 | $490 |
| Propranolol Hcl | 23 | $466 |
| RivastigmineRivastigmine Tartrate | 11 | $347 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 15 | $327 |
| Fludrocortisone Acetate | 13 | $287 |
| Donepezil Hcl | 25 | $226 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Diego
- Chamindra LavertySan Diego$662K
- Hossein AnsariSan Diego$377K
- Revere KinkelSan Diego$266K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.